Fig. 3: Neutralization potency against SARS-CoV-2 variant pseudovriuses elicited by SARS-CoV-2 S6P-HBsAgs. | npj Vaccines

Fig. 3: Neutralization potency against SARS-CoV-2 variant pseudovriuses elicited by SARS-CoV-2 S6P-HBsAgs.

From: Self-assembling SARS-CoV-2 spike-HBsAg nanoparticles elicit potent and durable neutralizing antibody responses via genetic delivery

Fig. 3

The sera at 2 weeks post the second immunization with SARS-CoV-2 S2P(1-1206), S6P(1-1206), S6P-12-HBsAg or S6P-16-HBsAg were evaluated against SARS-CoV-2 D614G, B.1.351, B.1.617.2 and B.1.1.529 pseudoviruses. The ID50s were plotted in the box and whiskers format. The median ID50 was indicated by a horizontal line, and the data points in the median quartile of each group were boxed. The error bars represent 95% confidence interval. The immunogens and doses were indicated. The ID50s were plotted in a logarithmic scale as dot, diamond or triangle for 10, 2, and 0.4 µg doses, respectively. The data points were shown in beige, green, red and blue for S2P(1-1206), S6P(1-1206), S6P-12-HBsAg and S6P-12-HBsAg, respectively. The geometric mean ID50 for each group was listed below each group. The statistical analyses were performed using the two-way ANOVA test following log transformation of the data. *p < 0.05; **p < 0.01.

Back to article page